Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UVA-Riboflavin Crosslinking for Corneal Ectasia
NCT01325298Phase 2Unknown
- Sponsor
- Mercy Center for Corrective Eye Surgery
- Start
- Mar 2011
- Primary completion
- Mar 2014
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of riboflavin in keratoconus and corneal ectasia (2 arms), sponsored by Mercy Center for Corrective Eye Surgery. Primary endpoint: Change in corneal curvature at 6 months. Status: unknown.
02
Drugs
riboflavin
03
Conditions
keratoconuscorneal ectasia
Beyond the preview
Go deeper on NCT01325298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01325298.